Live tape
Top 8, mentions 7d10,784GOOGL2,064 mentions▲ +0.04SNDK1,523 mentions▲ +0.11SPCX1,495 mentions▲ +0.08NBIS1,421 mentions▲ +0.09HTZ1,232 mentions▲ +0.10NVDA1,190 mentions▲ +0.08META1,018 mentions▲ +0.03MSFT841 mentions▲ +0.06

Equity · Healthcare

SYRE

Spyre Therapeutics, Inc. · NasdaqGS

$100 +6.38% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart
Our own end-of-day closes 40 sessions
$120 $60 20 May 17 Jul

The line runs $71.92 on 20 May through $100 on 17 July, on a scale from $60 to $120. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of SYRE over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 40 sessions over that window: $71.92 on 20 May 2026 through $100 on 17 July 2026.

Market cap $8.8B
P/E (TTM) 61.4
52-week range $15 – $102
Avg volume 393.0K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 18, 2026

SYRE insider trades

SEC Form 4 · last 90 days · newest reported trade 7 Aug 2026
Open-market buys 0
Open-market sells 11
Net sold $12.78M
Non-trade filings 7
Date Insider Type Shares Value
07 Aug 2026 Albers Jeffrey W. Director Sell 23,000 $2.40M
03 Aug 2026 Burrows Scott L Chief Financial Officer Sell 7,500 $717K
03 Aug 2026 Turtle Cameron Chief Executive Officer Sell 15,000 $1.43M
01 Jul 2026 Burrows Scott L Chief Financial Officer Sell 7,500 $658K
01 Jul 2026 Sloan Sheldon Chief Medical Officer Sell 8,334 $731K
01 Jul 2026 Turtle Cameron Chief Executive Officer Sell 15,000 $1.32M
25 Jun 2026 Burrows Scott L Chief Financial Officer Sell 15,000 $1.31M
22 Jun 2026 HENDERSON MICHAEL THOMAS Director Sell 20,000 $2.00M
03 Jun 2026 Sloan Sheldon Chief Medical Officer Sell 8,333 $625K
01 Jun 2026 Burrows Scott L Chief Financial Officer Sell 7,500 $533K
01 Jun 2026 Turtle Cameron Chief Executive Officer Sell 15,000 $1.06M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
07 Aug 2026 Albers Jeffrey W. Director Option exercise 5,000 $52K
03 Aug 2026 Burrows Scott L Chief Financial Officer Option exercise 7,500 $109K
01 Jul 2026 Burrows Scott L Chief Financial Officer Option exercise 7,500 $109K
01 Jul 2026 Sloan Sheldon Chief Medical Officer Option exercise 8,334 $229K
25 Jun 2026 Burrows Scott L Chief Financial Officer Option exercise 15,000 $218K
03 Jun 2026 Sloan Sheldon Chief Medical Officer Option exercise 8,333 $229K
01 Jun 2026 Burrows Scott L Chief Financial Officer Option exercise 7,500 $109K

SYRE reported financials

SEC EDGAR XBRL

SYRE reported revenue of $0 for the fiscal year ended 31 Dec 2025. Net income over the same period was −$155.2M.

Figure Reported Period
Revenue $0 31 Dec 2025 fiscal year
Net income −$155.2M 31 Dec 2025 fiscal year
Total assets $1.2B 30 Jun 2026 at period end
Total equity $1.1B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

SYRE earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-1.09 —
31 Mar 2026 Q1 2026 $-0.74 —
31 Dec 2025 FY 2025 — —
30 Sep 2025 Q3 2025 $-1.24 —
30 Jun 2025 Q2 2025 $-1.09 —
31 Dec 2024 FY 2024 — —
30 Sep 2024 Q3 2024 $1.06 —
30 Jun 2024 Q2 2024 $0.59 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

SYRE institutional holders

SEC Form 13F

9 of the 45 institutional funds we track reported a SYRE position for the quarter ended 30 Jun 2026 — a combined $134.2M; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Marshall Wace Added +612.1% shares 991,693 $88.0M
Millennium Management Added +34.1% shares 196,712 $17.5M
Balyasny Asset Management Added +165.1% shares 147,042 $13.1M
Citadel Advisors Held (±25%) −4.7% shares 103,100 $9.2M
D. E. Shaw & Co. New position 26,452 $2.3M
AQR Capital Management Held (±25%) +9.9% shares 22,937 $2.0M
Two Sigma Investments New position 12,771 $1.1M
Man Group Held (±25%) −19.2% shares 7,714 $685K
Tudor Investment Corp Trimmed −68.4% shares 2,645 $235K
Baker Bros. Advisors Exited

Source: SEC EDGAR 13F filings

SYRE fails-to-deliver

SEC CNS data

On 22 Jul 2026, 961 shares of SYRE failed to deliver (about $99K) — the latest of 5 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
22 Jul 2026 961 $99K 0.001%
21 Jul 2026 4,468 $435K 0.005%
20 Jul 2026 821 $82K 0.001%
17 Jul 2026 2,395 $225K 0.003%
16 Jul 2026 56 $6K <0.001%
07 Jul 2026 6,039 $536K 0.007%

Source: SEC fails-to-deliver (CNS) data